The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma

Table 4

Comparison of new risk models for progression-free survival using the Heng and MSKCC risk models with 2000 bootstraps.

Model	Harrell’s C index	mean(difference), 95% CI (2.5%, 97.5% of difference)
Model A	0.594	Model B vs A: 0.017 ( -0.021, 0.057)
Model B	0.610
Heng risk model	0.614	Heng vs Model A: 0.034 ( -0.030, 0.103)
		Heng vs Model B: -0.009 ( -0.081, 0.058)
MSKCC risk model	0.569	mMSKCC vs Model A: -0.025 (-0.106, 0.054)
		mMSKCC vs Model B: -0.042 (-0.127, 0.036)
Heng risk model + DRR	0.639	Heng vs (Heng+DRR): -0.025 ( -0.082, 0.013)
Model C = mMSKCC risk model + AST	0.569	mMSKCC vs Model C -0.013 (-0.052, 0.015)
Model D = mMSKCC risk model + NLR + DRR	0.602	mMSKCC vs Model D: -0.046 (-0.117, 0.002)
		Model C vs Model D: -0.033 (-0.102, 0.020)

MSKCC, Memorial Sloan Kettering Cancer Center; AST, aspartate transaminase; NLR, neutrophil-to-lymphocyte ratio; CI, confidence interval.
Model A = Nephrectomy, AST.
Model B = Nephrectomy, NLR.